MEETINGS - Conference entitled Blood Product Safety & Transmissible Spongiform Encephalopathies (US) February 2002:
This article was originally published in Clinica
Cambridge Healthtech Institute's eighth annual Blood Product Safety & Transmissible Spongiform Encephalopathies conference will be held on February 4-7 2002 in Washington, DC. The first two days will focus on blood product safety and features lectures on implications of NAT testing for transfusion services, the EU system for licensing test kits, new therapeutic products and tissue safety regulations. The latter half of the event is dedicated to developments in diagnosing and screening for TSE, including cyclic amplification of protein misfolding. Both subjects are supported by poster displays and exhibits. Further information from Frederick Vargus on tel: +1 617 630 1300; fax: +1 617 630 1325; email: email@example.com
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.